ABSTRACT
We describe a novel class of acidic mPGES-1 inhibitors with nanomolar enzymatic and human whole blood (HWB) potency. Rational design in conjunction with structure-based design led initially to the identification of anthranilic acid 5, an mPGES-1 inhibitor with micromolar HWB potency. Structural modifications of 5 improved HWB potency by over 1000×, reduced CYP2C9 single point inhibition, and improved rat clearance, which led to the selection of [(cyclopentyl)ethyl]benzoic acid compound 16 for clinical studies. Compound 16 showed an IC80 of 24nM for inhibition of PGE2 formation in vitro in LPS-stimulated HWB. A single oral dose resulted in plasma concentrations of 16 that exceeded its HWB IC80 in both rat (5mg/kg) and dog (3mg/kg) for over twelve hours.
Subject(s)
Benzoates/chemistry , Benzoates/pharmacology , Drug Discovery , Microsomes/drug effects , Prostaglandin-E Synthases/antagonists & inhibitors , Animals , Crystallography, X-Ray , Dogs , Microsomes/enzymology , Prostaglandin-E Synthases/chemistry , RatsABSTRACT
Here we report on novel, potent 3,3-dimethyl substituted N-aryl piperidine inhibitors of microsomal prostaglandin E synthases-1(mPGES-1). Example 14 potently inhibited PGE2 synthesis in an ex vivo human whole blood (HWB) assay with an IC50 of 7nM. In addition, 14 had no activity in human COX-1 or COX-2 assays at 30µM, and failed to inhibit human mPGES-2 at 62.5µM in a microsomal prep assay. These data are consistent with selective mPGES-1-mediated reduction of PGE2. In dog, 14 had oral bioavailability (74%), clearance (3.62mL/(min*kg)) and volume of distribution (Vd,ss=1.6L/kg) values within our target ranges. For these reasons, 14 was selected for further study.
Subject(s)
Piperidines/chemistry , Piperidines/pharmacology , Prostaglandin-E Synthases/antagonists & inhibitors , A549 Cells , Animals , Crystallography, X-Ray , Dogs , Humans , Piperidines/pharmacokinetics , Rats , Species Specificity , Structure-Activity RelationshipABSTRACT
The farnesoid X receptor (FXR) is a member of the "metabolic" subfamily of nuclear receptors. Several FXR agonists have been reported in the literature to have profound effects on plasma lipids in animal models. To discover novel and effective therapies for dyslipidemia and atherosclerosis, we have developed a series of potent FXR agonists that robustly lower plasma LDL and vLDL in LDLr-/- mice. To this end the novel piperidinylisoxazole system LY2562175 was discovered. This molecule is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans. The synthesis and biological profile of this molecule is discussed.
Subject(s)
Dyslipidemias/drug therapy , Hypolipidemic Agents/chemistry , Indoles/chemistry , Isoxazoles/chemistry , Receptors, Cytoplasmic and Nuclear/agonists , Animals , Cholesterol/blood , Dogs , Double-Blind Method , Female , HEK293 Cells , Humans , Hypolipidemic Agents/pharmacokinetics , Hypolipidemic Agents/pharmacology , Indoles/pharmacokinetics , Indoles/pharmacology , Isoxazoles/pharmacokinetics , Isoxazoles/pharmacology , Macaca fascicularis , Male , Mice , Mice, Knockout , Rats , Rats, Sprague-Dawley , Receptors, LDL/genetics , Structure-Activity Relationship , Triglycerides/bloodSubject(s)
Acetamides/classification , Acetamides/therapeutic use , Anti-Bacterial Agents/classification , Anti-Bacterial Agents/therapeutic use , Gram-Positive Bacterial Infections/drug therapy , Oxazolidinones/classification , Oxazolidinones/therapeutic use , Acetamides/chemistry , Animals , Anti-Bacterial Agents/chemistry , Drug Resistance, Bacterial , Humans , Linezolid , Microbial Sensitivity Tests , Molecular Structure , Oxazolidinones/chemistryABSTRACT
We report a new class of non-nucleoside antivirals, the 7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides, some of which possess remarkable potency versus a broad spectrum of herpesvirus DNA polymerases and excellent selectivity compared to human DNA polymerases. A critical factor in the level of activity is hypothesized to be conformational restriction of the key 2-aryl-2-hydroxyethylamine sidechain by an adjacent methyl group.
